Publications in collaboration with researchers from Centro de Investigación Biomédica en Red de Cáncer (1)

2024

  1. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy

    International Journal of Gynecological Cancer, Vol. 34, Núm. 2, pp. 277-284